Accounts for approximately 10% of all ovarian serous carcinomas.
Distinct from other ovarian cancers by unique histologic, molecular and clinical manifestations.
Has a more indolent course and a more favorable prognosis compared to high-grade serous carcinomas of the ovary.
More resistant to chemotherapy than high-grade serous carcinomas of the ovary.
In a recurrent setting response rate to chemotherapy less than 4%.
KRAS mutations 20-40%, and BRAF mutations 5-33%.
Associated with increased frequency of expression of activated protein kinase (MAPK).
Expression of MAPK in low-grade serous ovarian cancers is 81% compared to 41% in high-grade lesions.
Selumetinib an oral potent, selective, small molecule inhibitor of MAPKMEH1/2 promising agent.